Drugs / Dendritic and Cytokine-induced Killer Cells
Dendritic and Cytokine-induced Killer Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01821495 | May 2013 → May 2018 | nasopharyngeal carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic and Cytokine-induced Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01821495 ↗ |
| Modality | Cell therapy | “Patients in group A will receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks).” NCT01821495 ↗ |